Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Shares Outstanding (Diluted Average) (2021 - 2024)

Historic Shares Outstanding (Diluted Average) for Pharmaceuticals (CASI) over the last 3 years, with Q4 2024 value amounting to $15.3 million.

  • Pharmaceuticals' Shares Outstanding (Diluted Average) rose 1482.08% to $15.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.3 million, marking a year-over-year increase of 1482.08%. This contributed to the annual value of $15.3 million for FY2024, which is 1482.08% up from last year.
  • Per Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $15.3 million for Q4 2024, which was up 1482.08% from $13.4 million recorded in Q4 2023.
  • Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $15.3 million during Q4 2024, with a 5-year trough of $13.4 million in Q4 2023.
  • Over the past 3 years, Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $13.6 million (recorded in 2021), while the average stood at $14.1 million.
  • Data for Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increase of 1482.08% (in 2024) and a maximum YoY decrease of 1482.08% (in 2024) over the last 5 years.
  • Over the past 3 years, Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $13.6 million in 2021, then dropped by 1.84% to $13.4 million in 2023, then grew by 14.82% to $15.3 million in 2024.
  • Its last three reported values are $15.3 million in Q4 2024, $13.4 million for Q4 2023, and $13.6 million during Q4 2021.